Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases. Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development.
Adverum Biotechnologies NASDAQ:
03/24/19 1:30 AM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Mar 18 2019
Summary ToggleAdverum Biotechnologies to Participate in Upcoming Conferences
- Mar 6 2019
Summary ToggleAdverum Biotechnologies Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
- Feb 28 2019
Summary ToggleAdverum to Present at the Cowen 39th Annual Health Care Conference
- Feb 13 2019
Summary ToggleAdverum to Present at the 8th Annual SVB Leerink Global Healthcare Conference
There are currently no events to display.